Mahammedi, Hakim
Centre Jean Perrin
6 papers on CoChatORCID 0000-0002-7596-2357
Most cited papers
- Verified
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment
Cited by 1,511
- Verified
Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial
Sharma, P., Pachynski, R. K., Narayan, V., Fléchon, A., Gravis, G., Galsky, M. D., Mahammedi, H., Patnaik, A., Subudhi, S. K., Ciprotti, M., et al. (2020) · Cancer Cell
Cancer Immunotherapy and BiomarkersProstate Cancer Treatment and Research
Cited by 406
- Verified
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., Crosby, M., Piulats, J. M., Fléchon, A., Wei, X. X., et al. (2024) · The Lancet
Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications
Cited by 362
- Verified
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Chi, K. N., Rathkopf, D., Smith, M. R., Efstathiou, E., Attard, G., Olmos, D., Lee, J. Y., Small, E. J., Pereira de Santana Gomes, A. J., Roubaud, G., et al. (2023) · Journal of Clinical Oncology
Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy
Cited by 355
- Verified
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors
Fizazi, K., Drake, C. G., Beer, T. M., Kwon, E. D., Scher, H. I., Gerritsen, W. R., Bossi, A., den Eertwegh, A. J. M. V., Krainer, M., Houede, N., et al. (2020) · European Urology
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment
Cited by 185
- Verified
LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)
Sartor, O., Castellano Gauna, D. E., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N. N., Crosby, M., Piulats Rodriguez, J. M., Flechon, A., Wei, X. X., et al. (2023) · Annals of Oncology
Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications
Cited by 71
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free